# Efficacy, Safety, and Immunogenicity of V260 in Healthy Chinese Infants (V260-024)

> **NCT02062385** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 4040 (actual)

## Conditions studied

- Rotavirus Gastroenteritis

## Interventions

- **BIOLOGICAL:** V260
- **BIOLOGICAL:** Placebo to V260
- **BIOLOGICAL:** OPV
- **BIOLOGICAL:** DTaP

## Key facts

- **NCT ID:** NCT02062385
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05-30
- **Primary completion:** 2015-06-11
- **Final completion:** 2015-06-11
- **Target enrollment:** 4040 (ACTUAL)
- **Last updated:** 2018-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02062385

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02062385, "Efficacy, Safety, and Immunogenicity of V260 in Healthy Chinese Infants (V260-024)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02062385. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*